Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis (vol 321, pg 175, 2019)

首页> 外文期刊>JAMA: the Journal of the American Medical Association >Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis (vol 321, pg 175, 2019)

【24h】

Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis (vol 321, pg 175, 2019)

机译：初始疾病修饰治疗的结合随后转换为二次进步多发性硬化（Vol 321，PG 175,2019）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《JAMA: the Journal of the American Medical Association》 |2020年第13期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词

相似文献

外文文献
中文文献
专利

1. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis (vol 321, pg 175, 2019) [J] . JAMA: the Journal of the American Medical Association . 2020,第13期

机译：初始疾病修饰治疗的结合随后转换为二次进步多发性硬化（Vol 321，PG 175,2019）
2. Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study (vol 26, pg 363, 2019) [J] . Lorscheider J., Kuhle J., Izquierdo G. Protein and peptide letters . 2020,第6期

机译：抗炎性疾病 - 修饰初级进步多发性硬化症中的治疗和残疾进展：队列研究（Vol 26，PG 363,2019）
3. Gut microbiota-dependent CCR9(+)CD4(+)T cells are altered in secondary progressive multiple sclerosis (vol 142, pg 916, 2019) [J] . Kadowaki Atsushi, Saga Ryoko, Lin Youwei, Brain: A journal of neurology . 2019,第Pta6期

机译：肠道微生物群依赖性CCR9（+）CD4（+）T细胞在二次进行多发性硬化症中改变（Vol 142，PG 916，2019）
4. Developing Diagnostic Biomarkers for Secondary Progressive Multiple Sclerosis using Selected Reaction Monitoring [C] . Yan Jia, Christine Jelinek, Scott Newsome, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2011

机译：使用选定的反应监测开发二次逐步多发性硬化的诊断生物标志物
5. Aging and Disease-modifying Therapies in Multiple Sclerosis: Insights from Clinical Trials and Registries [D] . Zhang, Yinan. 2021

机译：多发性硬化症中的衰老和疾病改性疗法：临床试验和注册管理机构的见解
6. Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis [O] . Peter Connick, Floriana De Angelis, Richard A Parker, 1983

机译：多发性硬化症-进行性多臂继发性随机试验（MS-SMART）：一项多臂IIb期随机，双盲，安慰剂对照的临床试验，比较了三种神经保护药在继发性进行性多发性硬化症中的疗效
7. Predictors of Health Utility in Relapsing–Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies [O] . Luis Hernandez, Malinda O’Donnell, Maarten Postma 2020

机译：复发储存和二次逐步多发性硬化症的卫生效用预测因素：对疾病改性疗法的未来经济模型的影响

Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis (vol 321, pg 175, 2019)

著录项

相似文献

相关主题

期刊订阅